Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 5/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902002 | 0.77 | TSHR (0.43) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL12535705 | 0.77 | PDPK1 (0.49) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL6907428 | 0.77 | LMNA (0.43) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL22292592 | 0.74 | LMNA (0.41) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL30947487 | 0.73 | DYRK1A (0.40) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL22488626 | 0.73 | CYP1A2 (0.43) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL18555761 | 0.73 | BCAT2 (0.42) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL408976 | 0.70 | DYRK1A (0.55) | LMNATSHRRAB9ASMN1; SMN2DYRK1A | |
| SCHEMBL28918223 | 0.70 | DYRK1A (0.38) | LMNATSHRADORA2ASLC6A4ADRA1A | |
| SCHEMBL12540751 | 0.70 | ACHE (0.35) | LMNATSHRADORA2ASLC6A4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091490-B2 | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091490-B2 | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20200247809-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2020-08-06 | — | — | US | disclosed |
| US-20200247809-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2020-08-06 | — | — | US | disclosed |
| EP-3548488-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | Oncotyrol Center for Personalized Cancer Medicine GmbH (AT) | 2019-10-09 | — | — | EP | disclosed |
| EP-3548488-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | Oncotyrol Center for Personalized Cancer Medicine GmbH (AT) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018099952-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018099952-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091490-B2 | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors | CDK4, CDK2, CDK3 | LMNA 3296/4885TSHR 4198/4885ADORA2A 1452/4885 |
| US-20200247809-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | CDK3, CDK4, CDK2 | LMNA 2773/4885TSHR 4482/4885ADORA2A 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.